Абиратерон CAS:154229-19-3

Применение: Он показан для использования в сочетании с преднизолоном для лечения метастатического рака простаты, резистентного к кастрации..

Абиратерон — препарат, используемый в сочетании с преднизолоном при метастатическом раке простаты, резистентном к кастрации. (ранее гормонорезистентный или гормонорезистентный рак предстательной железы) — то есть, рак простаты, не реагирующий на андрогенную депривацию или лечение антиандрогенами. It is formulated as the prodrug abiraterone acetate and marketed under the trade name Zytiga. Cadila Pharmaceuticals has recently started marketing Abiraterone acetate under the trade name Abretone.

After an expedited six-month review, abiraterone was approved by the U.S. Food and Drug Administration (FDA) in April 2011. In Phase III trials, it extended median survival to 14.8 месяцев против 10.9 months placebo, and the trial was stopped because of the successful outcome.

Он показан для использования в сочетании с преднизолоном для лечения метастатического рака простаты, резистентного к кастрации.. It has received FDA (28 April 2011), EMA (23 September 2011), MHRA (5 September 2011) and TGA (1 March 2012) approval for this indication. In Australia it is covered by the Pharmaceutical Benefits Scheme when being used to treat castration-resistant prostate cancer and given in combination with prednisone/prednisolone (subject to the conditions that the patient is not currently receiving chemotherapy, is either resistant or intolerant of docetaxel, has a WHO performance status of <2, and his disease has not since become progressive since treatment with PBS-subsidised abiraterone has commenced).